EDAP TMS Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

EDAP TMS şirketinin toplam hissedar öz sermayesi €42.6M ve toplam borcu €6.5M olup, bu da borç-öz sermaye oranını 15.2% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla €79.0M ve €36.4M dir.

Anahtar bilgiler

15.2%

Borç/özkaynak oranı

€6.47m

Borç

Faiz karşılama oranı	n/a
Nakit	€25.48m
Eşitlik	€42.64m
Toplam yükümlülükler	€36.40m
Toplam varlıklar	€79.04m

Son finansal sağlık güncellemeleri

Recent updates

Potential Upside For EDAP TMS S.A. (NASDAQ:EDAP) Not Without Risk

Dec 25

Is EDAP TMS (NASDAQ:EDAP) Using Debt In A Risky Way?

Oct 24

Slammed 35% EDAP TMS S.A. (NASDAQ:EDAP) Screens Well Here But There Might Be A Catch

Sep 07

Fewer Investors Than Expected Jumping On EDAP TMS S.A. (NASDAQ:EDAP)

Jul 24

There's Reason For Concern Over EDAP TMS S.A.'s (NASDAQ:EDAP) Massive 28% Price Jump

Mar 22

Does EDAP TMS (NASDAQ:EDAP) Have A Healthy Balance Sheet?

Mar 03

It's A Story Of Risk Vs Reward With EDAP TMS S.A. (NASDAQ:EDAP)

Jan 19

Investors Still Waiting For A Pull Back In EDAP TMS S.A. (NASDAQ:EDAP)

Aug 11

Is There An Opportunity With EDAP TMS S.A.'s (NASDAQ:EDAP) 20% Undervaluation?

Dec 19

EDAP TMS' (NASDAQ:EDAP) Solid Profits Have Weak Fundamentals

Nov 23

EDAP TMS stock falls 7% aftermarket on proposed ADS offering

Sep 22

EDAP TMS S.A. GAAP EPS of $0.06 beats by $0.09, revenue of $14.97M beats by $1.35M

Aug 24

EDAP's Focal One Revenue Is Set To Accelerate

Aug 08

Is EDAP TMS (NASDAQ:EDAP) Weighed On By Its Debt Load?

Jul 19

Acceleration At EDAP

Jan 11

EDAP TMS (NASDAQ:EDAP) Could Easily Take On More Debt

Jan 06

The Consensus EPS Estimates For EDAP TMS S.A. (NASDAQ:EDAP) Just Fell A Lot

Nov 25

EDAP's HIFU Progress Is Obscured By The Pandemic, But It's Real

Sep 07

EDAP's subsidiary names medTech industry veteran Ryan Rhodes as CEO

Jun 15

EDAP TMS S.A. (NASDAQ:EDAP) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

Apr 02

Analysts Are Betting On EDAP TMS S.A. (NASDAQ:EDAP) With A Big Upgrade This Week

Jan 24

Treatment with EDAP's HIFU ultrasound benefits in prostate cancer patients, study shows

Jan 14

New reimbursement rules for HIFU technology to favor EDAP TMS

Dec 09

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: EDAP 'nin kısa vadeli varlıkları ( €63.9M ) kısa vadeli yükümlülüklerini ( €29.4M ) aşıyor.

Uzun Vadeli Yükümlülükler: EDAP şirketinin kısa vadeli varlıkları ( €63.9M ) uzun vadeli yükümlülüklerini ( €7.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: EDAP şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: EDAP 'nin borç/öz sermaye oranı son 5 yılda 18.6% seviyesinden 15.2% seviyesine düştü.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: EDAP şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: EDAP serbest nakit akışı her yıl % 51.6 1 yıl yetecek nakit akışına sahip olacaktır.

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/24 21:27
Gün Sonu Hisse Fiyatı	2025/01/24 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

EDAP TMS S.A. 7 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Andrew D'Silva	B. Riley Securities, Inc.
null null	CG Capital
Swayampakula Ramakanth	H.C. Wainwright & Co.

EDAP TMS Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is EDAP TMS (NASDAQ:EDAP) Using Debt In A Risky Way?

Does EDAP TMS (NASDAQ:EDAP) Have A Healthy Balance Sheet?

Is EDAP TMS (NASDAQ:EDAP) Weighed On By Its Debt Load?

EDAP TMS (NASDAQ:EDAP) Could Easily Take On More Debt

Recent updates

EDAP TMS S.A. Appoints Joshua H. Levine to Board of Directors

EDAP TMS S.A. Announces First Pancreatic Cancer Patient Treated with Proprietary HIFU Technology

Potential Upside For EDAP TMS S.A. (NASDAQ:EDAP) Not Without Risk

Edap Tms S.A. Provides HIFI Study Publication Demonstrates Positive Outcomes with Focal One Robotic HIFU Versus Surgery in the Management of Prostate Cancer

EDAP TMS S.A. to Report Q3, 2024 Results on Nov 07, 2024

Is EDAP TMS (NASDAQ:EDAP) Using Debt In A Risky Way?

EDAP TMS S.A. Announces First Patients Treated in Phase I/Ii Study Evaluating Focal One Robotic Hifu for the Treatment of Benign Prostatic Hyperplasia (Bph)

Slammed 35% EDAP TMS S.A. (NASDAQ:EDAP) Screens Well Here But There Might Be A Catch

EDAP TMS S.A. Announces Resignation of Marc Oczachowski as Chairman of Board of Directors, Effective September 30, 2024

EDAP TMS S.A. to Report Q2, 2024 Results on Aug 28, 2024

Fewer Investors Than Expected Jumping On EDAP TMS S.A. (NASDAQ:EDAP)

EDAP TMS S.A. Announces Interim Results from Phase 3 Study Evaluating Robotic Hifu for the Treatment of Deep Infiltrating Endometriosis

EDAP TMS S.A. Appoints Fran Schulz to Board of Directors

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 35%, revenue upgraded

EDAP TMS S.A. to Report Q1, 2024 Results on May 16, 2024

Consensus EPS estimates fall by 11%, revenue upgraded

New minor risk - Profitability

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

There's Reason For Concern Over EDAP TMS S.A.'s (NASDAQ:EDAP) Massive 28% Price Jump

EDAP TMS S.A. to Report Q4, 2023 Results on Mar 27, 2024

EDAP TMS SA Announces FDA Breakthrough Device Designation for Focal One in the Treatment of Deep Infiltrating Rectal Endometriosis

Does EDAP TMS (NASDAQ:EDAP) Have A Healthy Balance Sheet?

EDAP TMS S.A. Announces Completion of Enrollment in Phase 3 Study Evaluating Focal One Hifu Therapy for the Treatment of Deep Infiltrating Rectal Endometriosis

It's A Story Of Risk Vs Reward With EDAP TMS S.A. (NASDAQ:EDAP)

EDAP TMS S.A. Appoints Francois Dietsch as Global Chief Accounting Officer

Less than half of directors are independent

EDAP TMS S.A. Announces Board Changes

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

EDAP TMS S.A. to Report Q3, 2023 Results on Nov 09, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Profitability

EDAP TMS S.A. Announces Board Changes

New major risk - Revenue and earnings growth

EDAP TMS S.A. to Report Q2, 2023 Results on Aug 24, 2023

Investors Still Waiting For A Pull Back In EDAP TMS S.A. (NASDAQ:EDAP)

Insufficient new directors

EDAP TMS S.A., Annual General Meeting, Jun 30, 2023

Consensus EPS estimates fall by 199%

Price target increased by 9.1% to US$15.00

First quarter 2023 earnings released: €0.20 loss per share (vs €0.011 profit in 1Q 2022)

EDAP TMS S.A. to Report Q1, 2023 Results on May 17, 2023

Price target increased by 12% to US$14.50

Full year 2022 earnings released: €0.085 loss per share (vs €0.022 profit in FY 2021)

Consensus EPS estimates increase by 36%

EDAP TMS SA Announces Positive Results from Phase 2 Study Evaluating Therapeutic High-Intensity Focused Ultrasound for the Treatment of Rectal Endometriosis

Is There An Opportunity With EDAP TMS S.A.'s (NASDAQ:EDAP) 20% Undervaluation?

Now 20% undervalued

EDAP TMS S.A. Announces Approval to Initiate Randomized Clinical Trial Evaluating Focal One® as a Potential Treatment for Rectal Deep Infiltrating Endometriosis

EDAP TMS' (NASDAQ:EDAP) Solid Profits Have Weak Fundamentals

Consensus EPS estimates have been upgraded

Third quarter 2022 earnings released: EPS: €0 (vs €0.03 loss in 3Q 2021)

Now -35% undervalued

EDAP TMS S.A. to Report Q3, 2022 Results on Nov 16, 2022

EDAP TMS S.A. has completed a Follow-on Equity Offering in the amount of $20.000003 million.

EDAP TMS S.A. has completed a Follow-on Equity Offering in the amount of $20.000003 million.

EDAP TMS stock falls 7% aftermarket on proposed ADS offering

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

EDAP TMS S.A. GAAP EPS of $0.06 beats by $0.09, revenue of $14.97M beats by $1.35M

EDAP's Focal One Revenue Is Set To Accelerate

EDAP TMS S.A. to Report Q2, 2022 Results on Aug 24, 2022

Is EDAP TMS (NASDAQ:EDAP) Weighed On By Its Debt Load?

EDAP TMS S.A., Annual General Meeting, Jun 30, 2022

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

EDAP TMS S.A. to Report Q1, 2022 Results on May 17, 2022

EDAP TMS S.A. to Showcase Its Focal One® Platform At the Annual Meeting of the American Urological Association

Price target decreased to US$12.00

Consensus EPS estimates have been downgraded.